Buckingham Research Upgrades Allergen (AGN) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- Wall St set to open lower as oil jump, high yields fuel inflation concerns
- Oil jumps as Middle East supply concerns persist amid shipping attacks
- Why Citi says the Fed could be setting up for a dovish surprise
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
- Lynx sees AI semiconductor rally extending into year-end
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- Sportradar to sell Synergy Sports coaching unit for $170M
- Rezolve AI (RZLV) Reiterated at Overweight by Cantor Fitzgerald on Positioning as Key Component in E-Commerce Stack
- Wall Street ends lower, off record highs, as Treasury yields climb
- Applied Digital (APLD) Tops Q1 EPS by 26c, Beats on Revenue
Analyst Comments on Allergen (AGN) as Investors Await Updated Valeant (VRX) Proposal
May 27, 2014 1:57 PM EDTWells Fargo maintained an Outperform rating on Allergen (NYSE: AGN). Analyst Larry Biegelsen expects Valeant Pharmaceuticals International (NYSE: VRX) to update its proposal tomorrow.
"VRX is expected to raise its bid for AGN tomorrow, perhaps including a higher cash component. We have to wait-n-see on the higher bid and AGN's ultimate response.... More



